FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

5 letters match. Newest first.

  1. Sourav K. Mishra, M.D. / All India Institute of Medical Sciences

    FDA warned clinical investigator Dr. Sourav K. Mishra at AIIMS Bhubaneswar over a doxorubicin liposome bioequivalence study that broke protocol and consent rules.

    High risk
  2. Mukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre

    FDA warned clinical investigator Dr. Mukesh Chandre over informed consent failures in a doxorubicin liposome bioequivalence study.

    High risk
  3. Melanie M. Hoppers, M.D./Physicians Quality Care

    FDA warns Dr. Melanie Hoppers over enrolling ineligible patients in a baloxavir marboxil influenza trial.

    High risk
  4. Robert J. Hayashi, M.D./Washington University School of Medicine, Department of Pediatrics

    FDA warned Dr. Robert J. Hayashi over protocol deviations in pediatric drug trials that exposed a child to unnecessary study drug and invasive procedures.

    High risk
  5. Adarsh Daswani, M.D.

    Clinical investigator Adarsh Daswani, M.D. failed to follow protocol dosing and oversight for an investigational drug study.

    High risk